Summary of PTC Therapeutics FY Conference Call Company Overview - **Company**: PTC Therapeutics (NasdaqGS:PTCT) - **Event**: FY Conference Call on March 11, 2026 - **Speakers**: CEO Matt Klein, CFO Pierre Gravier Industry and Product Focus - **Disease**: Phenylketonuria (PKU) - A rare genetic disorder where individuals cannot break down the amino acid phenylalanine, leading to severe neurological consequences if untreated - Approximately **17,000 individuals** in the U.S. and **58,000 globally** are affected by PKU - **Product**: Sephience - A new therapy for PKU patients, aimed at providing a safe and effective treatment option Core Insights and Arguments - **Market Opportunity**: - Significant unmet medical need exists for PKU therapies, as prior treatments (Kuvan and Palynziq) did not adequately serve the majority of patients [2][3] - Sephience is positioned to address this need with a favorable safety and tolerability profile, allowing patients to have more dietary freedom [10][12] - **Patient Demand**: - There is a strong desire among PKU patients for effective therapies that can improve their quality of life [10][12] - Early launch metrics show over **1,100 starts** and **$110 million in revenue** within the first five and a half months, primarily from the U.S. market [14] - **Launch Strategy**: - The company has mapped out **104 centers of excellence** to understand decision-making dynamics, which include not just physicians but also nurse practitioners and dieticians [15] - Initial uptake has been broad, with patients across all age groups and severity levels being prescribed Sephience [18] - **Patient Segmentation**: - Majority of patients starting on Sephience are those who have previously tried and failed other therapies, with a notable number of therapy-naive patients also beginning treatment [19] - The company is focusing on getting patients who are currently untreated onto Sephience before switching those already on other therapies [22] - **Adherence and Discontinuation Rates**: - Early data indicates low discontinuation rates, with most patients responding positively to the therapy [34][35] - The expectation is that adherence will remain high due to the perceived benefits of the therapy [34] Financial Guidance - **Revenue Projections**: - Guidance for Sephience revenues is set at **$700 million to $800 million** for the year, with a global opportunity exceeding **$2 billion** [36][38] Other Important Insights - **Huntington's Disease Program**: - The votoplam program is progressing, with plans for a phase 3 trial and potential for accelerated approval based on interim analysis [41][42] - **Pipeline Development**: - The company is advancing several early-stage programs, including a phase 1 study for a NLRP3 inhibitor and other promising therapies targeting various conditions [49][50] Conclusion - PTC Therapeutics is positioned to make a significant impact in the PKU market with Sephience, addressing a critical unmet need and demonstrating strong early launch metrics. The company is also advancing its pipeline in other therapeutic areas, indicating a robust growth strategy moving forward.

Core Insights - Neurocrine Biosciences presented new data from the KINECT-HD2 study, showing long-term safety, tolerability, and sustained improvements in chorea severity with once-daily INGREZZA (valbenazine) in adults with Huntington's disease [1][2] Study Findings - The KINECT-HD2 study involved 154 adult participants treated with INGREZZA for up to three years, demonstrating early and sustained improvements in chorea severity [2][7] - Improvements in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score were observed as early as Week 2, with a mean improvement of -3.4±0.3 at the lowest dose of 40 mg [5] - By Week 156, 77.8% of participants reported a "much improved" status on the Patient Global Impression of Change (PGI-C) score [5] Safety and Tolerability - INGREZZA was generally well tolerated, with treatment-emergent adverse events (TEAEs) consistent with its established safety profile [3][5] - The most common TEAEs included falls (42.9%), somnolence (25.3%), and fatigue (21.4%), with serious TEAEs occurring in less than 2% of participants [5] Efficacy Analysis - The study indicated that concomitant antipsychotic use had no effect on chorea improvement, suggesting that INGREZZA can be used alongside other medications without compromising efficacy [2][5] - Efficacy was maintained throughout the treatment period, with significant improvements noted at various time points from Week 2 to Week 156 [5] About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating chorea associated with Huntington's disease and tardive dyskinesia [7][8] - The drug is available in 40 mg, 60 mg, and 80 mg capsules, and offers a sprinkle formulation for patients with swallowing difficulties [9]

Core Insights - ClearPoint Neuro's medical device is significant in UniQure's strategy to combat Huntington's disease [1] Company Summary - ClearPoint Neuro provides a medical device that is integral to the treatment efforts for Huntington's disease by UniQure [1] - UniQure is leveraging ClearPoint Neuro's technology to enhance its capabilities in addressing Huntington's disease [1]

Core Insights - Neurocrine Biosciences announced significant reductions in cognitive and motor-related burdens in adults with Huntington's disease chorea treated with INGREZZA (valbenazine) capsules, based on new patient-reported post-hoc data from the KINECT-HD study [1][4] Group 1: Study Findings - The KINECT-HD study is the first clinical trial to show measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor in Huntington's disease patients [1][2] - In the 12-week Phase 3 KINECT-HD clinical trial, INGREZZA showed a significant reduction in chorea severity, with a placebo-adjusted mean reduction in the Total Maximal Chorea (TMC) score of 3.2 units (p<0.0001) [11] - Patient-reported analyses indicated greater reductions in cognitive and motor-related disease burden for INGREZZA compared to placebo across various domains, including memory loss and mobility limitations [3][4] Group 2: Cognitive and Motor-Related Improvements - Statistically significant improvements were observed in cognition-related items, such as memory loss (-0.9 for INGREZZA vs -0.2 for placebo) and decision-making abilities (-1.0 for INGREZZA vs -0.3 for placebo) [3] - For motor-related items, INGREZZA demonstrated larger reductions in scores compared to placebo, including abnormal movements (-1.5 for INGREZZA vs -0.8 for placebo) and impaired coordination (-1.0 for INGREZZA vs -0.4 for placebo) [3][5] Group 3: Background on Huntington's Disease - Huntington's disease is a hereditary progressive neurodegenerative disorder affecting approximately 41,000 adults in the U.S., characterized by motor, cognitive, and psychiatric symptoms [7] - Chorea, a common symptom of Huntington's disease, involves irregular and unpredictable movements that can interfere with motor coordination and daily activities [7] Group 4: About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating chorea associated with Huntington's disease and tardive dyskinesia [14][15] - The drug is designed for once-daily administration without the need for titration, making it convenient for patients [16]